Theravance Biopharma, Inc.
TBPH
$18.43
-$1.18-6.02%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 329.68M | 338.80M | 130.86M | 88.35M | 91.36M |
| Total Receivables | 18.27M | 21.92M | 15.35M | 68.44M | 16.85M |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | 6.75M | 5.57M | 4.06M | 4.28M | 8.27M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | -- | -- | -- | -- | -- |
| Total Current Assets | 354.70M | 366.29M | 150.26M | 161.07M | 116.48M |
|
|
|||||
| Total Current Assets | 354.70M | 366.29M | 150.26M | 161.07M | 116.48M |
| Net Property, Plant & Equipment | 31.71M | 33.13M | 34.46M | 35.77M | 37.12M |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 26.03M | 26.61M | 158.86M | 157.32M | 202.50M |
| Total Assets | 415.46M | 426.04M | 343.58M | 354.16M | 356.11M |
|
|
|||||
| Total Accounts Payable | 2.21M | 1.68M | 2.41M | 2.24M | 1.45M |
| Total Accrued Expenses | 20.21M | 15.37M | 12.43M | 13.28M | 11.30M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 10.91M | 10.90M | 10.81M | 10.71M | 4.20M |
| Total Finance Division Other Current Liabilities | 4.07M | 26.70M | 5.85M | 5.85M | 6.49M |
| Total Other Current Liabilities | 4.07M | 26.70M | 5.85M | 5.85M | 6.49M |
| Total Current Liabilities | 37.41M | 54.63M | 31.50M | 32.09M | 23.44M |
|
|
|||||
| Total Current Liabilities | 37.41M | 54.63M | 31.50M | 32.09M | 23.44M |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 33.68M | 35.56M | 37.35M | 39.11M | 40.79M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 111.69M | 110.99M | 108.75M | 107.42M | 106.23M |
| Total Liabilities | 182.78M | 201.19M | 177.60M | 178.62M | 170.45M |
|
|
|||||
| Common Stock & APIC | 1.15B | 1.15B | 1.15B | 1.14B | 1.14B |
| Retained Earnings | -920.65M | -924.27M | -979.10M | -965.52M | -950.00M |
| Treasury Stock & Other | 32.00K | -10.00K | -- | 7.00K | 50.00K |
| Total Common Equity | 232.68M | 224.85M | 165.98M | 175.55M | 185.65M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 232.68M | 224.85M | 165.98M | 175.55M | 185.65M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 232.68M | 224.85M | 165.98M | 175.55M | 185.65M |
|
|
|||||